Eli Lilly recorded $408 million in U.S. sales in 2025 for its eczema treatment Ebglyss during the drug’s first full year on the market. The company has also reported positive findings from a phase 3 study evaluating the IL-13 inhibitor in younger patients with moderate to severe Atopic Dermatitis.
According to the company, the trial included 363 patients between the ages of 6 months and 18 years who had moderate to severe atopic dermatitis. Participants were randomly assigned to receive either a placebo or a weight-based dose of Ebglyss. All patients were treated with topical steroids beginning two weeks before randomization and continuing throughout the study.
The study met its primary and key secondary endpoints at Week 16 by improving disease symptoms and providing skin clearance and itch relief. The primary outcome was measured using the Eczema Area Severity Index, which assesses the extent and severity of eczema symptoms. A meaningful response was defined as a 75% improvement from baseline on the index.
In the study, 63% of patients treated with Ebglyss achieved this level of improvement, compared with 22% of those who received a placebo.
Additional results were reported in secondary measures. Using the same EASI scale, 39% of patients receiving Ebglyss achieved a 90% improvement from baseline, compared with 11% of participants in the placebo group.
Disease status was also evaluated using the Investigator Global Assessment scale, which rates disease severity from 0, representing clear skin, to 4, representing severe disease. In the study, 44% of patients treated with Ebglyss reached scores of 0 or 1, indicating clear or almost clear skin. By comparison, 15% of patients receiving a placebo reached those ratings.
The trial also assessed changes in itching symptoms. A four-point improvement in pruritus scores was recorded in 35% of patients treated with Ebglyss, compared with 6% of those who received a placebo.
Lilly said it plans to submit the study data to regulators in the United States and other regions for a potential update to the drug’s labeling.
Atopic dermatitis occurs more frequently in children than in adults. In the United States, the condition affects about 9.6 million children, and roughly one-third of those cases are considered moderate to severe.
Adrienne Brown, president of immunology at Eli Lilly and Company, commented on the impact of the condition on younger patients and their families. “Children with moderate-to-severe atopic dermatitis often endure relentless skin flares, itch, and discomfort that can disrupt play, school, and daily life for patients and caregivers,” Brown said. She also stated that the treatment has already been used in adults and adolescents and has delivered results that help patients experience fewer flares, with the option of monthly maintenance dosing.
The U.S. Food and Drug Administration approved Ebglyss in September 2024 for the treatment of moderate to severe atopic dermatitis in adults and children aged 12 years and older who weigh at least 88 pounds.
Lilly obtained the therapy when it acquired California-based Dermira for $1.1 billion.
In Europe, the drug is commercialized by Almirall, which reported 2025 sales of 111 million euros, or approximately $125 million, for the treatment.
Within the atopic dermatitis market, Ebglyss competes with other biologic therapies, including Dupixent from Regeneron Pharmaceuticals and Sanofi, as well as Adbry from LEO Pharma. Dupixent is approved for patients aged six months and older.
Ebglyss Demonstrates Strong Clinical Outcomes
In the trial, Ebglyss significantly improved skin clearance and reduced itching compared to standard treatments. These results position Ebglyss as a promising therapy for managing moderate-to-severe atopic dermatitis in children.
A recent Phase 3 clinical trial has delivered promising results for a new treatment targeting children with atopic dermatitis. The study highlights meaningful progress in addressing a condition that affects millions of young patients worldwide.
Strong Clinical Outcomes
The therapy demonstrated significant improvements in skin clearance and a reduction in itching severity compared to existing treatment options. Many participants experienced noticeable relief, indicating the potential for a more effective management approach.
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
